PubMed Health⌕ Search

Biomedical subjects

R Aoyama

Publications and source records attributed to R Aoyama.

35 records · Page 2Linked to original sources
PubMed1983

[Clinical studies of T-1982 (cefbuperazone) in pediatric field].

T-1982 (cefbuperazone) is a newly developed cephamycin. Clinical studies on this drug were carried out and the results were as follows: Eighteen patients (pneumonia 13, purulent tonsillitis 1, acute bronchitis 1, cellulitis 1, urinary tract infection 2) were treated intravenously with daily 27.4-100.2 mg/kg of T-1982 in 3-4 divided dose for 3-6.7 days. The overall efficacy rate was 94.4%. No adverse reactions were observed. Abnormal laboratory data noted were liver dysfunction in 1 case (4.8%), eosinophilia in 2 cases (9.5%), and anemia in 1 case (4.8%).

Anti-Bacterial Agents↗
PubMed1982

[Basic and clinical studies on cefmenoxime in pediatric field].

Cefmenoxime (CMX) is a newly developed cephalosporin. Basic and clinical studies on this drug was carried out and the results were as follows. 1. Serum level and urinary recovery A 7 years old male was administered 10 mg per kilogram of CMX by one shot intravenous injection. Serum levels were 23.3 micrograms/ml at the time of 15 minutes after injection, 12.0 micrograms/ml at 30 minutes, 3.9 micrograms/ml at 1 hour, 2.0 micrograms/ml at 2 hours, and 0.3 micrograms/ml at 4 hours. In this same patient, 6-hour urinary recovery was 54.7%. 2. Clinical evaluation and adverse reaction Thirty-seven patients (upper respiratory infection 4, pneumonia 20, pyothorax 1, purulent lymphadenitis 1, cellulitis 2, sepsis 1 and urinary tract infection 8) were treated with CMX in doses of 30 approximately 212 mg/kg divided 3 approximately 4 times per day for 1.5 approximately 21 days intravenously. The overall efficacy rate was 94.6%. As to adverse reaction, exanthema and drug fever were observed in 1 patient respectively. Abnormal laboratory data noted were eosinophilia in 2.3%, and elevation of serum transaminase in 9.8%.

Cefmenoxime↗
PubMed1982

[Clinical studies on 9,3"-diacetylmidecamycin in respiratory tract infections in pediatric field (author's transl)].

Clinical studies on 9,3"-diacetylmidecamycin (MOM) was carried out in 31 patients with respiratory tract infections (acute pharyngitis 6, acute purulent tonsillitis 5, scarlet fever 1, acute bronchitis 6, pneumonia 13 cases), in dose of 12 approximately 34 mg/kg divided 3 per day for 3 approximately 19 days. The overally efficacy rate was 74.2%. As to adverse reaction, exanthema and diarrhea with abdominal pain were observed in each 1 patient. Eosinophilia and elevation of serum GPT were noted in each 1 patient.

Adolescent↗
PubMed1982

[Clinical studies on cefsulodin in the pediatric field].

Clinical studies on cefsulodin (CFS) in 6 patients with Pseudomonas aeruginosa infection were carried out and the results as follows. 1. Among 4 patients administered CFS intravenously, 3 patients (urinary tract infection 1, acute purulent otitis media 1, aspiration pneumonia 1) responded well. 2. Two patients with respiratory infection were treated CFS by nebulization. One responded well and another fair. 3. No side effects were observed.

Administration, Intranasal↗
PubMed1981

[A clinical study of cefotiam in pediatric field (author's transl)].

Cefotiam is a new semisynthetic cephalosporin antibiotic. The treatment with this drug was carried out in 12 cases of pediatric infection. The clinical response was observed in 92% of the cases. Cefotiam was found to be active against a variety of Gram-positive and Gram-negative bacteria. Neither marked side effects nor laboratory abnormalities were found with this treatment.

Adolescent↗
PubMed1981

A case of membranous glomerulonephritis in which positive to negative change of hepatitis B e antigen in glomeruli was observed.

9-year-old boy suffering from membranous glomerulonephritis (GN) associated with hepatitis B virus (HBV) infection was observed. In this case seroconversion from hepatitis B e antigen (HBeAg) to hepatitis B e antibody (HBeAb) could not be confirmed, but a change from HBeAg positive to negative in the glomeruli was observed, and electron-dense deposits (EDD) became translucent and urinary protein also turned negative. These findings apparently suggest the possibility that membranous GN in this case is closely concerned with the causation and development of HBeAg.

Child↗
PubMed1981

[Clinical experience with cefadroxil dry syrup in pediatric infections (author's transl)].

Cefadroxil was administered to 16 pediatric patients at dose levels ranging from 27 to 56 mg/kg daily for 5-9 consecutive days. Of 16 patients, 9 had urinary tract infections including 5 cases with nephrotic syndromes, 4 had respiratory tract infections including 2 cases with nephrotic syndromes, 3 had skin infections including 2 cases of pyoderma and 1 case of suppurative gingivitis, including 1 case with nephrotic syndrome. Clinical results obtained were 9 'excellent', 4 'effective' and 3 'ineffective' showing an efficacy ratio of 81%. Of 9 urinary tract infections, 5 patients exhibited bacteriuria and 3 had original pathogens persisting after treatment. In respiratory tract, skin and gingival infections, cefadroxil was either 'excellent' or 'effective' in all 7 patients. The above results demonstrate a distinctive feature of cefadroxil that attains a good cutaneous distribution after oral administration. The absorption of the drug was not adversely affected by a food intake. No significant side effects were observed in all 16 patients. Judging from our clinical results, cefadroxil is considered one of the valuable cephalosporin antibiotics in the treatment of pediatric infections.

Cefadroxil↗
PubMed1981

Monocyte function in idiopathic nephrotic syndrome in childhood.

The monocyte function in 2-15 year old patients with idiopathic nephrotic syndrome (INS) in childhood was studied in reference to the phagocytosis of sensitized red blood cells and NBT reduction. The monocyte function was found to be increased in fresh cases of INS. In the case of refractory INS not responding to steroid treatment, the monocyte function was normal or tended to be low.

Adolescent↗
PubMed1980

[Clinical studies of cefoperazone in pediatric field (author's transl)].

Clinical studies of cefoperazone (CPZ) were performed and the following results were obtained. 1) CPZ was intravenously administered at the daily dose of 35 approximately 107 mg/kg to 10 children with infection: urinary tract infection (6 cases), respiratory infection (3 cases), and acute enterocolitis (1 case). The overall efficacy rate was 80%, and in urinary tract infection including one case caused by Pseudomonas aeruginosa, efficacy rate was 100%. 2) The bloody stools were noted in one case, 2 days after the administration of CPZ, but improved gradually. No abnormal laboratory data were found.

Adolescent↗
PubMed1979

[A clinical observation of cefuroxime in pediatric field (author's transl)].

Cefuroxime, a new synthetic cephalosporin, was administered to 10 pediatric patients (6 with respiratory tract infection, 2 with urinary tract infection, 1 with sepsis of E. coli and 1 with enterocolitis). The clinical result was good and excellent in all the 10 cases. No side effect was observed in any of them.

Adolescent↗
PubMed1979

[Clinical experience with CS-1170 (author's transl)].

CS-1170 was administered in 6 cases of infections in the pediatric field and the clinical response was excellent in 3, fair in 1, poor in 1 and unknown in one. Cases of acute purulent osteomyelitis which was cured by the present drug were described in detail. Each case is summarized Table 1.

Acute Disease↗
PubMed1978

[A clinical study of PC-904 in pediatric field (author's transl)].

A clinical study of PC-904 was performed and the following results were obtained. 1) PC-904 was intravenously administered at the daily dosage of 20 approximately 120 mg/kg to 13 children; urinary tract infection (10 cases), acute pneumonia (1 case), sepsis (1 case) and purulent meningitis (1 case). The overall efficacy rate was 46.2%. 2) As to adverse reaction, eosinophilia was noted only in 2 patients. One neonate was treated with this drug, but no side effects were observed. 3) It was considered that PC-904 was a useful antibiotic drug for the second choice rather than the first.

Acute Disease↗